Novartis | NVS - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bausch Health Companies USD 24.5B 1.87B 2026-03
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Canopy Growth CAD 1.12B 12.54M 2026-03
Corcept Therapeutics USD 814.88M 21.77M 2026-03
Drreddys Laboratories INR 579.35B 573.08B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Glaxosmithkline GBP 62.87B 19.47B 2026-03
J&J USD 200.89B 1.68B 2026-03
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pacira USD 1.21B 56.38M 2026-03
Perrigo USD 7.98B 551.9M 2026-03
Pfizer USD 207.62B 542M 2026-03
Phibro Animal Health USD 1.45B 39.56M 2026-03
Prestige Brands USD 3.49B 430K 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Supernus Pharmaceuticals USD 1.5B 48.08M 2026-03
Zoetis USD 15.15B 313M 2026-03